Ligand tries again to squeeze money from lasofoxifene with Azure licensing deal
This article was originally published in Scrip
Executive Summary
San Diego, California-based Ligand Pharmaceuticals has signed a global licensing deal with newly formed Azure Biotech for a novel formulation lasofoxifene in an undisclosed women's health indication. This is the latest in a series of attempts from the company to squeeze some profit from a product long in development, which has had promising licensing deals and regulatory successes in the past but never resulted in sales.